SGLT-2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: A Review

A 43.9 KB text document authored by Yan Yang and last updated in April 2026. It is a review summarizing clinical evidence and elucidating the underlying mechanisms of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) for treating cardiovascular-kidney-metabolic syndrome.

Use Cases

• Summarize clinical evidence for SGLT-2i effects on renal and cardiovascular outcomes based on the review's synthesis.
• Analyze the mechanistic pathways of SGLT-2i, such as glycosuria and natriuresis, described in the document.
• Inform treatment strategies for CKM syndrome stages 2–4 based on the review's recommendations.

Strengths

• Document is licensed under CC-BY-4.0, permitting open sharing and adaptation.
• Focuses on a specific, recently defined clinical entity (CKM syndrome) and a novel drug class (SGLT-2i).

Limitations

• Row count and column-level documentation are absent; data structure must be inferred after download.
• The 43.9 KB file size suggests a limited scope, likely a single review article rather than a large dataset.

Provenance

Source

figshare, authored by Yan Yang.

Collection Method

Likely a literature review compiled by the author.

Time Range

Covers evidence from the last decade up to the document's 2026 update.

Freshness

Last updated 2026-04-10 05:59:48.

Geography

null